Product Description
A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors. Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ganetespib)
Mechanisms of Action: HSP90 Inhibitor, TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Madrigal
Company Location: Eastern America
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Non-Small-Cell Lung Cancer|Myelodysplastic Syndrome|Leukemia
Phase 2: Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer|Hemangiosarcoma|Prostate Cancer|Adenocarcinoma|Gastrointestinal Cancer|Triple Negative Breast Cancer|Neurofibrosarcoma|Pancreatic Cancer|Small Cell Lung Cancer|Mesothelioma|Leukemia|Non-Small-Cell Lung Cancer|Myelodysplastic Syndrome|Breast Cancer|Acute Myeloid Leukemia|Melanoma|Colorectal Cancer|Preleukemia|Gastrointestinal Stromal Tumors|Lung Cancer|Pleural Cancer
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Male Breast Cancer|Non-Small-Cell Lung Cancer|Myelodysplastic Syndrome|Oropharyngeal Cancer|Head and Neck Cancer|Hepatocellular Carcinoma|Sarcoma|Squamous Cell Carcinoma|Multiple Myeloma|Transitional Cell Carcinoma|Lung Cancer|Thoracic Cancer|Adenocarcinoma|Cervical Cancer|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Blast Crisis|Gastrointestinal Cancer|Esophageal Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Colorectal Cancer|Acute Myeloid Leukemia|Acute Lymphoid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03783949 |
EUDARIO | P2 |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2023-09-01 |
2023-09-15 |
||
NCT01579994 |
NCT01579994 | P1 |
Completed |
Lung Cancer |
2020-12-28 |
2021-01-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT02389751 |
GUARDIAN-1 Trial | P1 |
Completed |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Thoracic Cancer|Cervical Cancer |
2019-07-16 |
2019-08-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02060253 |
NCT02060253 | P1 |
Completed |
Male Breast Cancer |
2018-06-01 |
2019-03-20 |
Treatments |
|
NCT02192541 |
14-C-0150 | P1 |
Terminated |
Sarcoma|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma |
2016-02-25 |
2019-03-20 |
Treatments |
|
NCT02334319 |
IRB00070264 | P1 |
Terminated |
Squamous Cell Carcinoma|Head and Neck Cancer|Oropharyngeal Cancer |
2016-02-01 |
2019-03-20 |
||
NCT01485835 |
IRB00049962 | P1 |
Completed |
Multiple Myeloma |
2015-09-01 |
2019-03-19 |
Treatments |
|
NCT01554969 |
IRB00054181 | P1 |
Completed |
Colorectal Cancer |
2015-03-01 |
2019-03-19 |
Treatments |
|
NCT01042379 |
I-SPY | P2 |
Recruiting |
Triple Negative Breast Cancer|Hemangiosarcoma |
2030-12-01 |
2026-05-07 |
||
2017-004058-40 |
EUDARIO: European Trial on enhanced DNA Repair Inhibition in Ovarian Cancer | P2 |
Active, not recruiting |
Ovarian Cancer |
2022-07-24 |
2022-03-13 |
Treatments |
|
NCT01590160 |
MESO-02 | P2 |
Completed |
Lung Cancer|Mesothelioma|Pleural Cancer |
2019-11-05 |
2019-11-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2012-001598-10 |
MESO-02 | P2 |
Completed |
Mesothelioma |
2019-11-05 |
2022-03-13 |
Treatments |
|
NCT02008877 |
SARC023 | P2 |
Completed |
Neurofibrosarcoma |
2018-04-01 |
2019-03-20 |
Treatments |
|
2013-003868-31 |
GANNET53: Ganetespib in metastatic, p53 mutant, platinum-resistant ovarian cancer | P2 |
Completed |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2017-12-04 |
2022-03-13 |
Treatments |
|
NCT02012192 |
GANNET53 | P2 |
Terminated |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2017-11-30 |
2019-08-14 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT02261805 |
NCT02261805 | P2 |
Terminated |
Small Cell Lung Cancer |
2016-10-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT01560416 |
NCT01560416 | P2 |
Completed |
Breast Cancer |
2016-06-26 |
2026-03-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Trial Status |
|
NCT01962948 |
GYN-064 | P2 |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2016-05-09 |
2022-09-30 |
Primary Endpoints |
|
NCT01167114 |
NCT01167114 | P2 |
Completed |
Gastrointestinal Cancer |
2016-05-01 |
2023-11-03 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT01677455 |
Enchant | P2 |
Completed |
Triple Negative Breast Cancer |
2015-04-01 |
2019-03-19 |
Treatments |
|
2012-000558-71 |
2012-000558-71 | P2 |
Completed |
Triple Negative Breast Cancer |
2015-03-17 |
2022-03-13 |
Treatments |
|
ACTRN12612000848808 |
AMLM20 | P3 |
Terminated |
Leukemia|Myelodysplastic Syndrome |
2017-02-23 |
2026-02-15 |
Treatments |
|
NCT01798485 |
Galaxy 2 | P3 |
Terminated |
Adenocarcinoma|Non-Small-Cell Lung Cancer |
2015-12-01 |
2019-03-19 |
Treatments |
|
NCT02637375 |
IRB15-0848 | N/A |
Withdrawn |
Triple Negative Breast Cancer |
2018-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2012-004349-34 |
Galaxy-2 | P3 |
Terminated |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2015-10-06 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/16/2024 |
News Article |
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix |
|
12/22/2020 |
News Article |
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612 |